[Circulatory dysfunction syndrome associated with liver cirrhosis]

Area of Science:

• Hepatology and Gastroenterology
• Cardiovascular Physiology
• Nephrology and Pulmonology

Context:

• Portal hypertensive patients exhibit splanchnic arterial relaxation as a key pathological feature.
• This relaxation leads to reduced splanchnic vascular resistance, causing circulatory dysfunction syndrome (CDS).
• CDS involves decreased effective blood volume and hormonal dysregulation, impacting multiple organ systems.

Purpose:

• To elucidate the pathophysiology of circulatory dysfunction syndrome (CDS) in portal hypertension.
• To detail the clinical manifestations and complications of advanced CDS.
• To outline current therapeutic strategies for managing CDS and its sequelae.

Summary:

• Splanchnic arterial relaxation is central to CDS development in portal hypertension, characterized by low arterial pressure and high cardiac output.
• Complications include hepatorenal syndrome, hepatopulmonary syndrome, cardiac dysfunction (portopulmonary hypertension, portal cardiomyopathy), and gastrointestinal bleeding.
• Management focuses on vascular filling (albumin), splanchnic vasoconstriction (beta-blockers, vasopressin analogs), cardiac output reduction, and vasoprotective therapies.

Impact:

• Understanding CDS pathophysiology aids in developing targeted therapies for portal hypertensive patients.
• Effective management of CDS can mitigate severe complications, improving patient outcomes and quality of life.
• This research highlights the systemic impact of portal hypertension, emphasizing the need for integrated treatment approaches.